Next Generation Sequencing (NGS) has the potential to unlock causative factors from our genetic material. Because of the sheer magnitude, precision and utilizable nature of the output data, a wealth of information will soon be available from studies completed using NGS. Avance Biosciences is offering GMP/GLP next generation DNA Sequencing services using Illumina’s state-of-art MiSeq and HiSeq systems.
Nucleic acids are extracted from your high quality test sample
Library is prepared using randomly fragmented DNA, followed by ligation with custom linkers
The library is amplified in arrays using clonal amplification methods and PCR to create clonal clusters
Arrays are sequenced
Data analyses and in-depth data analyses
Our industry-leading quality system is designed and maintained to support drug and device research and development, GLP pre-clinical trials, cGMP biomanufacturing, and clinical trials.
Avance Biosciences provides biological testing services to support regulatory submission for clients around the world. These services are conducted under the requirements of Good Laboratory Practices and Current Good Manufacturing Practices as promulgated by the U.S. Food and Drug Administration 21 CFR Part 58 and 21 CFR Part 210 and 211, as well as Good Manufacturing Practice according to ICH Q7, where applicable to the laboratory services provided.
The MiSeq system provides up to 5 Mb of output from DNA with an input as low as 10 ng; it is used for small genome sequencing such as bacteria, viruses, and other microbes as well as 16S rRNA amplicon sequencing for microbial identification and metagenomic analysis.
The HiSeq system is utilized for large genomes greater than 5 Mb; it is used to analyze tumors, determine disease causes, select plants and animals for agricultural breeding programs, and find genetic variations among populations.